Comparative in vitro activity of Meropenem, Imipenem and Piperacillin/tazobactam against 1071 clinical isolates using 2 different methods: a French multicentre study

<p>Abstract</p> <p>Background</p> <p>Meropenem is a carbapenem that has an excellent activity against many gram-positive and gram-negative aerobic, facultative, and anaerobic bacteria. The major objective of the present study was to assess the <it>in vitro </it>activity of meropenem compared to imipenem and piperacillin/tazobactam, against 1071 non-repetitive isolates collected from patients with bacteremia (55%), pneumonia (29%), peritonitis (12%) and wound infections (3%), in 15 French hospitals in 2006. The secondary aim of the study was to compare the results of routinely testings and those obtained by a referent laboratory.</p> <p>Method</p> <p>Susceptibility testing and Minimum Inhibitory Concentrations (MICs) of meropenem, imipenem and piperacillin/tazobactam were determined locally by Etest method. Susceptibility to meropenem was confirmed at a central laboratory by disc diffusion method and MICs determined by agar dilution method for meropenem, imipenem and piperacillin/tazobactam.</p> <p>Results</p> <p>Cumulative susceptibility rates against <it>Escherichia coli </it>were, meropenem and imipenem: 100% and piperacillin/tazobactam: 90%. Against other <it>Enterobacteriaceae</it>, the rates were meropenem: 99%, imipenem: 98% and piperacillin/tazobactam: 90%. All <it>Staphylococci</it>, <it>Streptococci </it>and anaerobes were susceptible to the three antibiotics. Against non fermeters, meropenem was active on 84-94% of the strains, imipenem on 84-98% of the strains and piperacillin/tazobactam on 90-100% of the strains.</p> <p>Conclusions</p> <p>Compared to imipenem, meropenem displays lower MICs against <it>Enterobacteriaceae</it>, <it>Escherichia coli </it>and <it>Pseudomonas aeruginosa</it>. Except for non fermenters, MICs90 of carbapenems were <4 mg/L. Piperacillin/tazobactam was less active against <it>Enterobacteriaceae </it>and <it>Acinetobacter </it>but not <it>P. aeruginosa</it>. Some discrepancies were noted between MICs determined by Etest accross centres and MICs determined by agar dilution method at the central laboratory. Discrepancies were more common for imipenem testing and more frequently related to a few centres. Overall MICs determined by Etest were in general higher (0.5 log to 1 log fold) than MICs by agar dilution.</p

Le système de santé en République démocratique populaire Lao (organisation et perspectives de la pharmacie de l'hôpital provincial de Khammouane, Thakhed)

LYON1-BU Santé (693882101) / SudocSudocFranceF

Mise au point d'une technique de PCR en temps réel pour le diagnostic des infections intestinales à Clostridium difficile

LYON1-BU Santé (693882101) / SudocSudocFranceF

Facteurs de risque associé à l'isolement d'une entérobactérie du groupe III C3G-R en réanimation (travail du laboratoire de bactériologie du Centre Hospitalier Lyon-Sud (Professeur Flandroit [sic] Flandrois) dirigé par le docteur Monique Chomarat)

LYON1-BU Santé (693882101) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF

Identification des entérobactéries par séquençage (application au diagnostic bactériologique en pratique quotidienne)

LYON1-BU Santé (693882101) / SudocSudocFranceF

Audit de l'organisation et des pratiques de prescription de l'antibiprophylaxie dans un centre hospitalo-universitaire

LYON1-BU Santé (693882101) / SudocSudocFranceF

Gram-positive infections in neutropenic patients: glycopeptide antibiotic choice

International audienc

Coagulase-negative staphylococci emerging during teicoplanin therapy and problems in the determination of their sensitivity

International audienc

Susceptibility to Aminoglycosides of 63 Strains of Stomatococcus mucilaginosus Isolated from Sputum

International audienc